Lorlatinib with chemotherapy1

Phase 1

Lorlatinib with chemotherapy1 is one of 13 therapeutic programs targeting High Grade Glioma. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

High Grade GliomaRecruiting

High Grade GliomaPhase 1

Recruiting

Competition

Competitive Landscape

16 competitors in High Grade Glioma

#DrugCompanyPhaseTrials

Opdualag

Bristol-Myers Squibb

Phase 2

1 2

Temodar

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Phase 2

3 3

Ojemda

Day One Biopharmaceuticals

Phase 2

1 4

Ziagen

GSK

Phase 1

1 5

Norvir

AbbVie

Phase 1

1 6

Lorbrena

Pfizer

Phase 1

1 7

Epivir

GGlaxo Dba Glaxosmithkline

Phase 1

1 8

Mepron

GGlaxo Dba Glaxosmithkline

Phase 1

1 9

PEP-CMV

UUniversity of Florida

Phase 2

1 10

Lutathera

AAdvanced Accelerator Applications

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2035

Phase 1Recruiting

High Grade Glioma

NCT06333899

Clinical

Trials by Indication[1]

High Grade Glioma1 trial

A Pilot Study of Lorlatinib for Treatment of Children With Newly Diagnosed High-Grade Glioma With ROS-1 (ROS Proto-Oncogene 1, Receptor Tyrosine Kinase) or ALK (Anaplastic Lymphoma Kinase) Fusion

Recruiting·NNationwide Children's Hospital·Phase 1·NCT06333899·15 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Lorlatinib with chemotherapy1. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Lorlatinib with chemotherapy1. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Nationwide Children's Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 1[1]
Company: NNationwide Children's Hospital

Lorlatinib with chemotherapy1

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q2 2035

Trials by Indication[1]

High Grade Glioma1 trial

References

Drug Info

Quick Facts

Related News